RT Journal Article
SR Electronic
T1 Clinical Impact of <em>IDH1</em> Mutations and <em>MGMT</em> Methylation in Adult Glioblastoma Multiforme
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.30.22273163
DO 10.1101/2022.03.30.22273163
A1 Mahmoud, Magda Sayed
A1 Khalifa, Mohamed K.
A1 Nageeb, Amira M
A1 El-Arab, Lobna Ezz
A1 El-Mahdy, Manal
A1 Ramadan, Amal
A1 Hashim, Maha
A1 Bakr, Noha
A1 Swellam, Menha
YR 2022
UL http://medrxiv.org/content/early/2022/04/07/2022.03.30.22273163.abstract
AB Background Genetic aberrations and epigenetic alterations have been reported in different types of cancer. Impact of Isocitrate dehydrogenase1 (IDH1) and O6-methylguanine-DNAmethyltransferase (MGMT) in glioblastoma multiforme (GBM) have been of great interest due to their implications in prediction of prognosis of several types of cancer. Authors aimed to investigate the clinical role of IDH1 mutation and MGMT methylation pattern among GBM patients versus non-neurooncological diseases (NND) patients and their impact on survival criteria.Methods Formalin-Fixed Paraffin-Embedded (FFPE) tissue sections of 58 GBM and 20 non-onconeurological diseases patients were recruited and IDH1 mutation were detected using Cast-PCR technology and MGMT methylation was detected using Methyl II quantitative PCR approach. Their results were assessed with other clinicopathological criteria and assess its correlation with survival patterns.Results IDH1 mutation was detected among 15 GBM cases (15/58) and it was not reported among NND (P=0.011). Receiver operating characteristic (ROC) curve were plotted to discriminate between MGMT methylation among studied groups. Patients with MGMT methylation ≥ 66% was reported as high methylation, which was recorded significantly in 51.7% and 100% of GBM cases and NND, respectively. Both showed significant difference with performance status, while MGMT methylation was significantly related with tumor size and tumor location. IDH1 mutation and MGMT methylation reported significant increase with GBM patients revealed complete response to treatment. Survival pattern was better for IDH1 mutation and MGMT high methylation as compared to IDH1 wild type or MGMT low-moderate methylation, respectively and favorable survival was detected when both were combined than using either of them alone.Conclusion Detection of IDH1 mutation and MGMT methylation among GBM patients could aid in prediction of their response to treatment and their survival patterns, and their combination is better than using any of them alone.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis paper is based upon work supported by Science, Technology &amp; Innovation Funding Authority (STDF) Basic and Applied Research Support Grant Project (BARG) [No.25562]. The instruments listed in the current study were purchased through a grant from Science Technology &amp; Innovation Funding Authority (STDF) through Capacity Building Grant Fund (CBG) [No. 4940], Egypt.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:After getting ethical approval from Medical Ethical Committee of National Research Centre (ID#20110)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAvailability of data and material: no data available to be shared.ARMSAmplification Refractory Mutation SystemBRCABreast cancer geneCTVClinical Target VolumeCRcomplete responseCTComputerized tomographyDNAdeoxyribonucleic acidECOGEster Clinical Oncology GroupEGFRepidermal growth factor receptorGBMglioblastoma multiformeHEHematoxylin-eosinIDHisocitrate dehydrogenaseLODlimit of detectionMRIMagnetic resonance imagingNNDnon-neurooncological diseasesMGMTO6-methylguanine-DNAmethyltransferasePTV-1planning Target Volume